Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAL-001 Lactobacillus Quadruple Live Capsule in Postmenopausal Atrophic Vaginitis
ChiCTR2300070002Phase 2Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atrophic vaginitis comparing KAL-001 experimental arm with Placebo control arm (2 arms). Primary endpoint: vaginal microecology. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
KAL_001
03
Conditions
atrophic vaginitis
Beyond the preview
Go deeper on ChiCTR2300070002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070002.